Member Info for Aether

"They've done a great job in extremely difficult times."

They've done a terrible job in extremely opportune times. A larger pharmaceutical company with more resources and political influence would have got this over the line but they chose to go it alone instead.

We are currently a penny share as a consequence of their great job. This might still turn to zero. Nothing is guaranteed here.

"When an experiment fails, you don't immediately blame the scientists who ran it."

Straw man argument. I am critical of the decisions made by the management.

"...even if Synairgen continue to go it alone."

The company lacks the experience and political influence to get this over the line.

If this gets on one or more paid clinical trials, the sp will rise to a new trading range but I doubt it will be back to pre RNS highs.

Then, if we have a successful P3, there will be a TO.

As it is, I will be glad to break-even and extricate myself from this company.

The product can save peoples lives and needs to be made available.

Thanks for the clarification, Docdaneeka.

Prior to The RNS, when attempting to calculate the sp, the formula proposed was for every £1billion in sales = £5.

Is this still valid?

What would the anticipated sales be now compared to previously?

HelloSanDiego nails it:

"I can't see Polygon putting in a bid of £1 early next year while a trial is underway (or a bid of less than £1 being in any shareholder's interests), and I can't see another firm offering £200m plus for a drug that failed its last trial. I think Polygon's probably just expecting success from another trial and anticipates profits from its 29.99%."

This will be a long wait.

Billy,

There's a link to it here in one of the comments:

https://www.lse.co.uk/ShareChat.asp?ShareTicker=SNG&thread=E8BBBE94-AC51-4595-B48E-DA4697BBB82E

If I recall correctly, there are a limited number of places and when they get filled up they don't take on anyone else until an account becomes dormant and a position becomes available to join. Hope that helps :)

Thanks, Docdaneeka!

Thanks, Billy.

You're becoming hysterical, shrill and abusive, SD2019. You're demeaning yourself and showing your lack of character.

Studying RM was like David Attenborough studying gorillas in the Congo.

Except the gorilla would have planned and managed the clinical trial better.

Again, if, *****IF***** we can extricate ourselves from this share, good Activ-2 data will be needed in the next few weeks AND then inclusion on a paid for clinical trial.

As I said on another post, then we will probably be TO before the trial is complete. Probably after it passes a futility test.

I think this can come good it requires patience.

£1 to break even.

GLA.

We've been here before with body language, for example, studying and commenting on RM.

"Golly doesn't He look cheerful and positive. He MUST know something! Martha I'm going all in with the pension pot and the kid's uni money!! Bentley or Lambo, yacht or plane, Umbria or Tuscany. It's been de-risked, a random stranger told me on a bulletin board, lots of them. ALL OF THEM. And a fellow draws a rocket for take-off AND another random stranger told everyone, yes, you heard that right EVERYONE not to sell their GOLDEN tickets. And, and, and well what do you mean 'you need to calm down and think about it rationally like you did when you were making money'? What do you mean woman! I *FEEL* good. That's all that matters. And random strangers on the internet agree with me! Oh and RM is looking cheerful and positive."

It doesn't really reveal anything.

They know they have to look cheerful to inspire confidence in the company.

It's basic business skills.

The earliest we can get out will be after good Activ-2 data and inclusion on a paid for trial.

*IF* a larger pharmaceutical company is interested they will then buy before phase 3 is complete because it will be cheaper.

Activ-2 data soon.

It should be good since we progressed to P3. Also, it was specifically stated in an RNS that investigators from the NIH and company are in discussions to redraft the protocol and find a suitable trial.

Then, hopefully, new paid for clinical trial.

One step at a time!

*IF* this happens then we should be TO before any P3 trial results, especially if we pass the futility tests, because it will be cheaper than after a successful P3 trial.

It's surprising the number of unwell posters that have a commerical pilot as a friend.

dunk there's a lot of fubar creepy weirdo stalkers following this board. There's a broadmoor vibe to them.

What other poster do we know who has "a friend who is a pilot"?

Polygon will block a low-ball offer but the sock puppet already knows that.

It's a troll account.

Green bin it.

If a trial is successful, how much...

The paid trials will be government run and designed albeit from the RNS with input from the company.

dippfs

There was an RNS recently when it was stated that officals from both SNG and NIH were working to find an appropriate trial and redraft the protocol for the company.